tbuckley/cabot-search huggingface dataset:
Abstract 195: Engineering Shear-thinning Injectable Biomimetic Hydrogel to Repair Damaged Cardiac Tissue
Authors: Arghya Paul, Renae Waters, Settimio Pacelli, Aparna Chakravarti
Journal: Circulation Research (2017)

Rationale: In acute myocardial infarction (AMI), prognosis and mortality rate are closely related to the infarct size and the progression of post-infarction cardiac failure. Delivery of stem cell derived secretome (miR, growth factor, exosome) has presented a new approach for the treatment of AMI. However, protection of bioactivity of delivered secretome and its retention at target site remains a challenge that can lead to sub-optimal results. Methods and Results: Here, we present a shear-thinning nanocomposite tissue adhesive hydrogels composed of synthetic 2% silicate nanoplatelets and 5% gelatin as injectable platform for effectively deliver adipose stem cell-derived secretome. This nanogel forms a highly crosslinked gel which could sustain high strain and recover its original stiffness once the strain is removed. This property is essential to prevent the material from flowing out of the therapeutic site once injected and thus enabling longer retention of the secretome. We used a novel microfluidic technology to harness high concentration secretome from stem cell spheroids before loading it to the hydrogel. The hydrogel-secretome (HS) demonstrated significantly enhanced in vitro angiogenic activity and cardioprotection. We hypothesized that the HS might promote angiogenesis cooperatively with the delivered secretome. To evaluate our hypothesis, we employed a rat AMI model and injectable HS gel to the heart. A significant increase in capillary density and reduction in infarct sizes were noted in the infarcted hearts with HS treatment compared with ctrl infarcted hearts treated with saline, hydrogel or secretome only groups. Furthermore, the HS showed significantly higher cardiac performance in echocardiography (62.8±3 of ejection fraction vs 45.2±5 ctrl, P &lt; 0.05, n=6) 3 weeks post MI. In combination with bioprinting and microscale technologies, we have also sucessfully fabricated an elastomeric scaffold with this HS gel that can be used as a cardiac patch. Conclusion: The combination of injectability, rapid mechanical recovery, cargo retention ability, bioprintability and ability to attenuate progression of cardiac dysfunction makes this HS gel a versatile platform for cardiac biotherapeutics and tissue engineering applications.
Improvement in health status at 3 months in the COURAGE trial: Seattle angina questionnaire results William S. Weintraub, John Spertus, Emir Veledar, Cheryl Lewis, Elizabeth Mahoney, Pamela Hartigan, David J. Maron, Koon Teo, Paul Casperson, Karen Potter, Sandra B. Dunbar, Robert A. O'Rourke, William E. Boden. Emory University, Atlanta, GA, West haven Veterans Administration Hospital, West Haven, CT
Journal: Journal of the American College of Cardiology (2001)
Disulfiram doesn't always prevent drinking
Authors: E. R. Gonzalez
Journal: JAMA (1981)

Alcoholic patients sometimes contend that they can continue to drink while taking disulfiram (Antabuse). It may be true. Evidence of the claim's veracity comes from a study presented at the recent New Orleans meeting of the American Society for Clinical Pharmacology and Therapeutics and subsequently published by J. E. Peachey, MD, head, behavioral pharmacotherapy clinic, clinical institute, Addiction Research Foundation, Toronto (<i>Lancet</i>1981;1:943-944). Peachey and co-workers reported that nonalcoholic paid volunteers who were given disulfiram, then small alcoholic drinks, were able to imbibe additional ethanol without untoward effects. In the double-blind study, 18 volunteers were randomly assigned to receive either disulfiram, 3.5 mg each evening, calcium carbimide (Temposil), 0.7 mg twice a day, or placebo over a 48-hour period. Calcium carbimide is a "sensitizing drug" that is similar to disulfiram but not available in the United States. Twelve hours after the last dose of drug or placebo, the volunteers were
Immunometabolic rewiring in tumorigenesis and anti-tumor immunotherapy
Authors: Xin Lian, Kailin Yang, Renliang Li, Maomao Li, Jing Zuo, Bohao Zheng, Wei Wang, Ping Wang, Shengtao Zhou
Journal: Molecular Cancer (2022)

Cellular metabolism constitutes a fundamental process in biology. During tumor initiation and progression, each cellular component in the cancerous niche undergoes dramatic metabolic reprogramming, adapting to a challenging microenvironment of hypoxia, nutrient deprivation, and other stresses. While the metabolic hallmarks of cancer have been extensively studied, the metabolic states of the immune cells are less well elucidated. Here we review the metabolic disturbance and fitness of the immune system in the tumor microenvironment (TME), focusing on the impact of oncometabolites to the function of immune cells and the clinical significance of targeting metabolism in anti-tumor immunotherapy. Metabolic alterations in the immune system of TME offer novel therapeutic insight into cancer treatment.
Consensus Conference. Limb-sparing treatment of adult soft-tissue sarcomas and osteosarcomas
Journal: JAMA (1985)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
ITALY
Journal: JAMA (1949)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Association News
Authors: Robert E. Eskildson
Journal: JAMA (1906)

fled to the extent that the formula instead of being placed on the bottle was to be lodged with the health department.The manufacturers still objected, and as no further alterations could be obtained they decided not to send their preparations to New Zealand.Mr. Syme stated that evidently the vendors of patent medicines clearly realized that once the real nature and commercial value of their preparations became publicly known, there could be no demand for them at their present extravagant prices.In commenting on this the British Medical Journal says: "Happy country! which has got rid of this pestilential traffic; but we wonder what our halfpenny press would say if any legislator were bold enough to venture to propose a bill which would deprive them of a large part of their receipts.Some day the public may wake up to the desir¬ ability of taking action to check the sale of preparations which are either poisonous or fraudulent, as those which are neither would have nothing to fear from such a law."Evi¬ dently the press in Great Britain and her colonies is as much under the dominion of the "patent medicine" man as it is in the United States.
Observations on the Caesarean Section and on Other Obstetric Operations
Authors: T. Radford
Journal: BMJ (1865)

CHAPTrER VI. O1;erations intended to save the Life of the Mother, and also that of the Infant.(Concluded.)llI.-OnPremature Labour.The induction of premature labour was first performed by Dr. Mlacaulay in England in the year 1736.But, although this is the fact, and though the importance of the operation is acknowledged and its a(loption sanc- tioned by the mlost enminent, British obstetricians, yet, if we conisalt statistics, we shall find it has only been limitedly employed, in comparison with its practical importance.There is no recognition of this practice in the statute-book, to distinguish it from that abuse of it which is committed for criminal purposes.In this respect, it is estimated in the same way as some other operations which I shall consider in. the subse- quent part of these remarks, being only sanctioned by the law of custom.This is an unwvise legislativc omission, because it permits wicked men to cover their crimes under the pretension of a legitimiate act.On this account, therefore, great caution should be exercised whenever this operation is intended to be performed.It is justifiable on moral grounds, and it is approved of on every professional and social principle.The object of its performance is noble
Remarkably high prevalence of small dense low-density lipoprotein particles in Japanese men with coronary heart disease, irrespective of the presence of diabetes Shinji Koba, Tsutomu Hirano, Masayuki Shibata, Takeshi Kondo, Hiroshi Suzuki, Mikitaka Murakami, Takashi Katagiri. Showa University School of Medicine, Tokyo, Japan
Journal: Journal of the American College of Cardiology (2001)
Increased Reactive Oxygen Species–Mediated Ca <sup>2+</sup> /Calmodulin-Dependent Protein Kinase II Activation Contributes to Calcium Handling Abnormalities and Impaired Contraction in Barth Syndrome
Authors: Xujie Liu, Suya Wang, Xiaoling Guo, Yifei Li, Roza Ogurlu, Fujian Lu, Maksymilian Prondzynski, Sofia de la Serna Buzon, Qing Ma, Donghui Zhang, Gang Wang, Justin Cotton, Yuxuan Guo, Ling Xiao, David J. Milan, Yang Xu, Michael Schlame, Vassilios J. Bezzerides, William T. Pu
Journal: Circulation (2021)

Mutations in tafazzin (TAZ), a gene required for biogenesis of cardiolipin, the signature phospholipid of the inner mitochondrial membrane, causes Barth syndrome (BTHS). Cardiomyopathy and risk of sudden cardiac death are prominent features of BTHS, but the mechanisms by which impaired cardiolipin biogenesis causes cardiac muscle weakness and arrhythmia are poorly understood.We performed in vivo electrophysiology to define arrhythmia vulnerability in cardiac-specific TAZ knockout mice. Using cardiomyocytes derived from human induced pluripotent stem cells and cardiac-specific TAZ knockout mice as model systems, we investigated the effect of TAZ inactivation on Ca2+ handling. Through genome editing and pharmacology, we defined a molecular link between TAZ mutation and abnormal Ca2+ handling and contractility.A subset of mice with cardiac-specific TAZ inactivation developed arrhythmias, including bidirectional ventricular tachycardia, atrial tachycardia, and complete atrioventricular block. Compared with wild-type controls, BTHS-induced pluripotent stem cell-derived cardiomyocytes had increased diastolic Ca2+ and decreased Ca2+ transient amplitude. BTHS-induced pluripotent stem cell-derived cardiomyocytes had higher levels of mitochondrial and cellular reactive oxygen species than wild-type controls, which activated CaMKII (Ca2+/calmodulin-dependent protein kinase II). Activated CaMKII phosphorylated the RYR2 (ryanodine receptor 2) on serine 2814, increasing Ca2+ leak through RYR2. Inhibition of this reactive oxygen species-CaMKII-RYR2 pathway through pharmacological inhibitors or genome editing normalized aberrant Ca2+ handling in BTHS-induced pluripotent stem cell-derived cardiomyocytes and improved their contractile function. Murine Taz knockout cardiomyocytes also exhibited elevated diastolic Ca2+ and decreased Ca2+ transient amplitude. These abnormalities were ameliorated by Ca2+/calmodulin-dependent protein kinase II or reactive oxygen species inhibition.This study identified a molecular pathway that links TAZ mutation with abnormal Ca2+ handling and decreased cardiomyocyte contractility. This pathway may offer therapeutic opportunities to treat BTHS and potentially other diseases with elevated mitochondrial reactive oxygen species production.
Abstract 407: Divergent Functions of Thrombospondin Genes in Mammals
Authors: Tobias G Schips, Davy Vanhoutte, Matthew Brody, Nathan Correll, Andoria Tjondrokoesoemo, Michelle Sargent, Marjorie Maillet, Jeffery D Molkentin
Journal: Circulation Research (2017)

Thrombospondin (Thbs) proteins are multidomain, matricellular proteins comprised of 5 genes that each share similar domains and have been largely ascribed the same functional characteristics. The Thbs protein family is divided in 2 subgroups based on multimerization as trimers, (group A: Thbs1 and 2), or as pentamers (group B: Thbs3, 4 and 5). Thbs proteins modulate various aspects of cell- matrix interactions. Thbs1 and 2 can also alter angiogenesis and modulate MMP- as well as TGF beta activity. More recently, we have shown that they can also serve an intracellular chaperone function along the secretory pathway in response to ER stress (Lynch et. al. Cell 2012). The overall aim of this study is to functionally compare the two Thbs subgroups and elucidate their involvement in cardiac homeostasis and disease. Hence we analyzed gain and loss of function mouse models for Thbs1 as a representative of group A and Thbs3 for group B. Our overall conclusion was that Thbs4 serves a protective function in the heart while Thbs1 and Thbs3 are either overtly maladaptive or they predispose to worsening heart disease with injury stimulus. Taken together, this is the first study comparing Thbs subfamilies, unraveling previously unrecognized functions of Thbs1 and 3 in the mammalian heart, which appears to oppose the protective function of Thbs4.
Errors in Figures
Authors: Phillip Knebel
Journal: JAMA Surgery (2020)

Francis X. Guyette, MD, MPH; Joshua B. Brown, MD, MSc; Mazen S. Zenati, MD, PhD; Barbara J. Early-Young, BSN; Peter W. Adams, BS; Brian J. Eastridge, MD; Raminder Nirula, MD, MPH; Gary A. Vercruysse, MD; Terence O’Keeffe, MD; Bellal Joseph, MD; Louis H. Alarcon, MD; Clifton W. Callaway, MD, PhD; Brian S. Zuckerbraun, MD; Matthew D. Neal, MD; Raquel M. Forsythe, MD; Matthew R. Rosengart, MD, MPH; Timothy R. Billiar, MD; Donald M. Yealy, MD; Andrew B. Peitzman, MD; Jason L. Sperry, MD, MPH; STAAMP Study Group
Genetic counseling throughout the life cycle
Authors: Leslie J. Ciarleglio, Robin L. Bennett, Jennifer Williamson, Jessica B. Mandell, Joan H. Marks
Journal: Journal of Clinical Investigation (2003)

As the definition of genetic counseling continues to evolve , so does the application of genetic counseling services in all areas of medicine and throughout the human life cycle. While governmental policy, economics, ethics, and religion continue to influence society's views regarding the necessity of testing germ cells for mutations to prevent the birth of an affected child or predicting whether healthy adults will develop future life-threatening illness, patient autonomy in the choice of whether to know, or not know, one's genetic make-up remains a core principle of genetic counseling.
Palliative radiosurgery for localized pancreatic cancer in the elderly.
Authors: Steven Sckolnik, Rotem Fishel, Erkut Hasan Borazanci, Albert Amini, Amar Thosani
Journal: Journal of Clinical Oncology (2022)

583 Background: At least 15% of patients diagnosed with localized pancreatic cancer are medically unfit for surgical resection or systemic therapy. Traditionally, these patients are enrolled in palliative care with symptom management alone. With local progression of their disease, they may experience pain, obstruction, weight loss and nausea. Radiosurgery is a localized high dose conformal therapy allowing for noninvasive treatment of pancreatic cancer. This study retrospectively examines the role of palliative radiosurgery as monotherapy for elderly patients who are not candidates for standard of care therapy. Methods: From 2017-2021, 28 patients over the age of 80 with biopsy confirmed pancreatic adenocarcinoma and localized disease by imaging were retrospectively evaluated. All had been deemed not to be candidates for surgical resection or systemic chemotherapy. Outcomes were reviewed to evaluate patient characteristics, local control, quality of life, ECOG status and survival duration. Results: Median patient age was 84 years (range 80-99). All 28 patients received SBRT radiosurgery to the pancreas with 35-40Gy in 5 fractions with photon LINAC platform. Mean ECOG score was 1.2 at time of treatment. At 6 month follow up, 18 patients were alive with a mean ECOG of 1.4. Four patients reported grade 2 acute GI toxicity in the first three months with no late toxicity reported. Eight patients developed local progression while fourteen patients developed distant metastatic disease. Six patients at least one year out from treatment have no evidence of disease progression. Median overall survival is 10.8 months. Conclusions: Pancreatic radiosurgery is a safe and effective method of palliative therapy for elderly patients who are not candidates for surgical resection or systemic therapy. It can provide durable local control, relief of pain and obstructive symptoms, is well tolerated with minimal toxicity and provides favorable survival when compared to palliative care alone.
<i>Notes from the Field:</i> HIV Outbreak During the COVID-19 Pandemic Among Persons Who Inject Drugs — Kanawha County, West Virginia, 2019–2021
Authors: Rebecca B. Hershow, Suzanne Wilson, Robert A. Bonacci, Molly Deutsch-Feldman, Olivia O. Russell, Sherri Young, Shannon McBee, Erica Thomasson, Shawn Balleydier, Miracle Boltz, Vicki Hogan, Amy Atkins, Nancy Worthington, Robert McDonald, Monica Adams, Anne Moorman, Danae Bixler, Stephen Kowalewski, Melinda Salmon, R. Paul McClung, Alexandra M. Oster, Kathryn G. Curran
Journal: MMWR Morbidity and Mortality Weekly Report (2022)

During October 2019, the West Virginia Bureau for Public Health (WVBPH) noted that an increasing number of persons who inject drugs (PWID) in Kanawha County received a diagnosis of HIV. The number of HIV diagnoses among PWID increased from less than five annually during 2016-2018 to 11 during January-October 2019 (Figure). Kanawha County (with an approximate population of 180,000*) has high rates of opioid use disorder and overdose deaths, which have been increasing since 2016,† and the county is located near Cabell County, which experienced an HIV outbreak among PWID during 2018-2019 (1,2). In response to the increase in HIV diagnoses among PWID in 2019, WVBPH released a Health Advisory§; and WVBPH and Kanawha-Charleston Health Department (KCHD) convened an HIV task force, conducted care coordination meetings, received CDC remote assistance to support response activities, and expanded HIV testing and outreach.
GASTROJEJUNOCOLIC FISTULA
Authors: H. M. STENHOUSE
Journal: JAMA (1924)

What we expect to find and the condition that exists inside the abdomen may be decidedly different. This is the more striking after previous operation in the peritoneal cavity. In the normal, healthy state there are the stomach, the more solid viscera and the small intestines, intricately coiled and folded, gliding softly and maintaining their integrity. But disease or trauma distorts the arrangement, and leaves adhesions to alter function. A not uncommon result of gastro-enterostomy is the fixation of the transverse colon in the vicinity of the anastomosis. Should the cause of the original ulceration not be removed, new ulcers may occur in spite of the drainage of the gastric contents provided for by the operation. The outcome of such an ulcer perforating the walls of the jejunum and the colon at the site of fixation is a gastrojejunocolic fistula. Early recognition and intervention offer fair chances for recovery. Delay
Abstract OT-28-06: A phase 1, first in human study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor in subjects with HER2 overexpressing solid tumors
Authors: Natalie Grover, Debora Barton, Amy Ronczka, Joshua Bauml
Journal: Cancer Research (2021)

Abstract Adoptive T cell therapies have led to remarkable advances among patients with hematologic malignancies, but not in those with solid tumors. Macrophages are actively recruited into and more abundantly present in the tumor microenvironment (TME) as compared to T cells. Tumor- associated macrophages (TAMs), typically evince immunosuppressive behavior, but when engineered to be proinflammatory, may be an ideal vector to administer adoptive cellular therapy in solid tumors. Furthermore, insertion of a CAR confers on the macrophages the ability to selectively recognize and phagocytose antigen overexpressing cancer cells. CAR macrophages can also potentially interact with, stimulate, and present neoantigens to T cells. Human Epidermal Growth Factor Receptor 2 (HER2) is overexpressed in many cancers, including but not limited to breast and gastroesophageal cancers (Table 1). CT-0508 is a cell product comprised of autologous monocyte-derived pro-inflammatory macrophages expressing an anti-HER2 CAR. In vitro and in vivo studies have shown that CT-0508 leads to cancer cell phagocytosis sparing normal cells, decreased tumor burden and prolonged survival. CT-0508 cells were safe in a semi-immunocompetent mouse model of human HER2 overexpressing ovarian cancer. This is a FIH Phase 1 study to evaluate safety, tolerability, cell manufacturing feasibility, trafficking, and preliminary evidence of efficacy of investigational product CT-0508 on approximately 18 subjects with locally advanced (unresectable) or metastatic solid tumors overexpressing HER2 who have failed available therapies including anti-HER2 therapies when indicated.Filgrastim, will be used to mobilize autologous hematopoietic progenitor cells for monocyte collection by apheresis. CT-0508 cell product will be manufactured, prepared and cryopreserved. Group 1 will receive CT-0508 infusion split over D1, 3 and 5. Subjects will be continually assessed for acute and cumulative toxicity. Dose limiting toxicities will be observed and addressed by a Safety Review Committee. Group 2 will receive the full CT-0508 infusion on D1. Pre and post treatment biopsies and blood samples will be collected to investigate correlates of trafficking, persistence, TME modulation, immune response and safety. Citation Format: Natalie Grover, Debora Barton, Amy Ronczka, Joshua Bauml. A phase 1, first in human study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor in subjects with HER2 overexpressing solid tumors [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr OT-28-06.